Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell

Meeting

Thursday, 09. February 2023

Physicians Session
13:15 - 14:45 Plenary
PS01 - Clinical Indications I - Lymphomas
Chair: Marie José Kersten, NL
PS01-1 Large B Cell Lymphoma (LBCL) 13:15 - 13:35
Speaker: Anna Sureda, ES

PS01-2 Mantle Cell Lymphoma (MCL) / Follicular Lymphoma (FL) 13:35 - 13:55
Speaker: Ulrich Jaeger, AT

PS01-3 Resistance 13:55 - 14:20

Speaker: Marco Ruella, US

PS01-4 Microbiome 14:20 - 14:45

Speaker: Marcel Van den Brink, US

Poster Session
13:15 - 20:00 Poster Area
Poster
Mathematical Optimization of Personalized CAR-T Cell Products 13:15 - 13:15
Poster Presenter: John J. L. Jacobs, NL

Nurse-led Long Term Follow up Clinic 13:15 - 13:15

Poster Presenter: Olivia Lamb, GB

Cooccurrence of CRS and ICANS in Anti-CD19 CAR T-cell 13:15 - 13:15

Treatments
Poster Presenter: Vibhu Agarwal, US

Molecular Mechanisms of CAR-T Cell Response in MM 13:15 - 13:15

Poster Presenter: Juan R. Rodriguez-Madoz, ES

Three-year Follow-up of ZUMA-3: Brexucabtagene Autoleucel in 13:15 - 13:15

R/R B-ALL
Poster Presenter: Tsveta Hadjivassileva, GB

Real-time Prediction of CAR-T Cell Concentrations and Optimal 13:15 - 13:15

Harvest Times
Poster Presenter: Stephen Goldrick, GB

In vivo Tumor Microscopy in a Medulloblastoma Mouse Model 13:15 - 13:15

Poster Presenter: Julika J. Herold, DE

Anti-tumor Response of TCR-engineered iNKT Cells 13:15 - 13:15

Poster Presenter: Gloria Delfanti, IT

Expanding Access to CART Therapy via Local Institutions 13:15 - 13:15

Poster Presenter: Miri Assayag, IL

Outcomes of Subsequent Therapies after Axi-cel or SOC in 13:15 - 13:15

ZUMA-7

1 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Poster Presenter: Marie José Kersten, NL

Coagulopathy and Endothelial Activation in CAR-T Therapy 13:15 - 13:15

Poster Presenter: Eugenio Galli, IT

Cost-effectiveness of Brexucabtagene for Refractory/Relapsed 13:15 - 13:15

Acute Lymphoblastic Leukemia

Combination of CAR30 and Chimeric Costimulatory Receptor 13:15 - 13:15

Enhances Antitumor Activity
Poster Presenter: Eva Escudero López, ES

CAR T-cells vs Allogeneic Transplantation in Relapsed Large B- 13:15 - 13:15

cell Lymphoma
Poster Presenter: Peter Dreger, DE

CD3e Gene Editing to Redirect Regulatory T Cells 13:15 - 13:15

Poster Presenter: Weijie Du, DE

Adoptive Cell Therapy of Acute Leukemia across MHC-barriers 13:15 - 13:15

Poster Presenter: Michela Consonni, IT

Durable Responses Assessment after Brexu-cel for R/R MCL in 13:15 - 13:15
ZUMA-2
Poster Presenter: Marie José Kersten, NL

Mouse Model of CAR-related ICANS Development Following 13:15 - 13:15

hCD19 CAR-T Treatment
Poster Presenter: Rita El Khoury, IT

T2EVOLVE Consortium for the Optimization of Engineered T- 13:15 - 13:15

cells Toxicity Models
Poster Presenter: Monica Casucci, IT

LMP2A-targeting CAR-T Cells and TRUCKs to Treat EBV- 13:15 - 13:15

associated Malignancies
Poster Presenter: Stefanie Thoelke, DE

Microbial Metabolite-guided Engineering of CAR T Cells 13:15 - 13:15

Poster Presenter: Maik Luu, DE

Engineering Molecular Switches for Functional Control of CAR 13:15 - 13:15

T Cells
Poster Presenter: Michael W. Traxlmayr, AT

CAR T-cells Targeting FLT3-positive AML 13:15 - 13:15

Poster Presenter: Maya Pedersen, DK

Co-stimulatory Domain CD28/CD40 of CAR 13:15 - 13:15

Poster Presenter: Wannakorn Khopanlert, TH

Redirection of T Cells and NK Cells by CD3-zeta Editing 13:15 - 13:15

Optimized Allogeneic CAR-T Therapies for AML with SB 13:15 - 13:15

Transposons
Poster Presenter: Juan R. Rodriguez-Madoz, ES

2 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

CXCR4-overexpressing CD33.CAR-CIK Eliminates BM AML 13:15 - 13:15

Cells
Poster Presenter: Marta Biondi, IT

A Gene Signature in Leukapheresis Predicts Anti-CD19 CAR-T 13:15 - 13:15

Cell Outcome
Poster Presenter: Cristiana Carniti, IT

CD84-targeted CART-cell Therapy for the Treatment of Acute 13:15 - 13:15

Myeloid Leukemia
Poster Presenter: Lorena Pérez-Amill, ES

First Real World Data from the Austrian CAR-T Network 13:15 - 13:15
Poster Presenter: Jakob Daniel Rudzki, AT

Different Editing Outcomes of CRISPR PE in HEK293T and T- 13:15 - 13:15

cells
Poster Presenter: Karl Petri, US

Donor-derived CAR-T Cells Co-infusion with T-depleted HSCT 13:15 - 13:15

Poster Presenter: Arina Rakhteenko, RU

Prophylactic Corticosteroids with Axi-cel: ZUMA-1 Cohort 6 13:15 - 13:15

2-year Follow-up
Poster Presenter: Tom van Meerten, NL

CAR-T Cells with Improved Migration and Suppression 13:15 - 13:15

Protection

Disease Stage Affects CAR-T Cell Function 13:15 - 13:15

Poster Presenter: Juan R. Rodriguez-Madoz, ES

Clinical Grade ROR1 CAR T-cells against Haematologic and 13:15 - 13:15
Solid Malignancies
Poster Presenter: Katrin Mestermann, DE

Safety Profiling of CAR T Cells in Human Tissues 13:15 - 13:15

Generation and Functional Analysis of HBV-specific FabCARs 13:15 - 13:15

Poster Presenter: Zhe Xie, DE

Pre-clinical Validation of Co-transduced CD19/BCMA Dual-CAR- 13:15 - 13:15

T Cells for NHL
Poster Presenter: Mireia Bachiller, ES

Monitoring CAR-T Cells: Looking for Early Biomarkers as 13:15 - 13:15

Predictive Factors
Poster Presenter: Belén Sierro-Martínez, ES

Myeloid Cells and CAR T Cells 13:15 - 13:15

Speaker: Camille Bigenwald, FR

Systematic Literature Review of Real-world Evidence on 13:15 - 13:15

Axicabtagene-ciloleucel and Tisagenlecleucel
Poster Presenter: Fang Sun, US

3 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Superiority of CD4+ CARTs 13:15 - 13:15

Poster Presenter: Qian Chen, DE

Dual Modified Primary CD33-directed CAR-NK Cells for 13:15 - 13:15

Treatment of AML
Poster Presenter: Nawid Albinger, DE

Early Management CRS and Outcome of DLBCL Treated with 13:15 - 13:15
CAR-T
Poster Presenter: Ana Africa Martin Lopez, ES

Unusual Toxicity after Brexucabtagene Autoleucel Treatment 13:15 - 13:15

Poster Presenter: Jacopo Mariotti, IT

Initial Clinical Results of Point-of-Care Manufactured GLPG5101 13:15 - 13:15

in RR NHL
Poster Presenter: Kirsten Saevels, BE

Cytotoxicity of CAR-T-cells from DLBCL Patients in High 13:15 - 13:15

Resolution Microscopy
Poster Presenter: Eva C Schwarz, DE

Update on HD-CAR-1 Trial: 3rd-generation CD19-directed CARTs 13:15 - 13:15

for Relapsed/Refractory CLL
Poster Presenter: Patrick Derigs, DE

TME Targeting CAR-T Cells for Solid Tumors 13:15 - 13:15

Poster Presenter: Juan R. Rodriguez-Madoz, ES

Rituximab + CFM/FLU Lymphodepletion Followed by Second 13:15 - 13:15

CART19 in B-ALL
Poster Presenter: Valentin Ortiz-Maldonado, ES

3G.CARTs for ALL 13:15 - 13:15

Poster Presenter: Michael Schmitt, DE

The Endothelium Involvement during CRS: First Reported Case 13:15 - 13:15
of CAR-VOD
Poster Presenter: Manuela Spadea, IT

Clonal Hematopoiesis and Manufacturing of CAR T- 13:15 - 13:15

lymphocytes

CECs in CAR-T cells Associated CRS and ICANS 13:15 - 13:15

Poster Presenter: Irene Defrancesco, IT

Cytopenias after CAR-T in Real World: Utility of CAR- 13:15 - 13:15

HEMATOTOX

Novel Modular SIRPalpha Based Chimeric Antigen Receptors 13:15 - 13:15

Poster Presenter: Jan Koski, FI

Initial Clinical Results of Point-of-Care Manufactured GLPG5201 13:15 - 13:15

in R/R CLL/SLL
Poster Presenter: Julio Delgado, ES

4 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Metabolic Reprogramming of CAR T Cell Phenotype 13:15 - 13:15

Poster Presenter: Mathias Wenes, CH

Proteasomal Inhibition Sensitizes AML Cells to CAR NK-cell 13:15 - 13:15

Mediated Killing
Poster Presenter: David Sedloev, DE

CAR-Treg for Systemic Lupus Erythematosus 13:15 - 13:15

Poster Presenter: Matteo Doglio, IT

Chasing the Epigenetic Landscape to Prevent CD19 Antigen 13:15 - 13:15

Escape
Poster Presenter: Narendra Varma Gottumukkala, CZ

Outcomes of T2Evolve Survey on CAR T Cell Analytical 13:15 - 13:15

Methods
Poster Presenter: Pacôme Lecot, FR

Inflammatory Reactions after CAR T-cell Therapy 13:15 - 13:15

Poster Presenter: Janneke W de Boer, NL

Viral Reactivation after CAR-T Cell Therapy 13:15 - 13:15

Poster Presenter: Elisabetta Xue, IT

Prognostic Impact of MTV in DLBCL Treated with CAR-T 13:15 - 13:15

Poster Presenter: Ana Africa Martin Lopez, ES

Impact of SARS-CoV-2 Vaccination and Prophylaxis on Car-T 13:15 - 13:15

Patients Journey
Poster Presenter: Eugenio Galli, IT

s-AML with KMT2A Rearrangement Following CAR-T for R/R 13:15 - 13:15
DLBCL

A Newly Reported ICANS-associated MRI Alteration after CAR-T 13:15 - 13:15

Cell Therapy
Poster Presenter: Flavio Pistolese, IT

Neurotoxicity of CD19-CAR-T-Cells: A Case Report 13:15 - 13:15

Poster Presenter: Conrad Weidt, DE

Glofitamab in Primary Mediastinal Large B-cell Lymphoma after 13:15 - 13:15

CAR T-cell Treatment Failure
Poster Presenter: Galina Petrova, RU

TP53 Mutations: Impact in Childhood Outcomes after CD19-CAR 13:15 - 13:15

T-cell Therapy
Poster Presenter: Anna Alonso-Saladrigues, ES

CRS after CAR-T Cell Therapy for MCL: A Case Report 13:15 - 13:15
Poster Presenter: Elenii Gavriilaki, GR

Effect of Glycine-Serine Linker on CD37CAR-T Efficacy 13:15 - 13:15

Poster Presenter: Wannakorn Khopanlert, TH

Immune Microenvironment of Patients Undergoing CAR T Cell 13:15 - 13:15

5 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Therapy
Poster Presenter: Ulrike Weirauch, DE

Evaluation of New Immunotherapeutic Targets for Multiple 13:15 - 13:15

Myeloma
Poster Presenter: Mégane Jassin, BE

Real World Experience CAR T-cell Early Failure Predictors 13:15 - 13:15
Poster Presenter: Sita Bhella, CA

Short-linker CD137-based anti-BCMA CAR 13:15 - 13:15

Poster Presenter: Sophia Stock, DE

ISIKOK-19 CAR T Cell in ALL with Extramedullary Disease 13:15 - 13:15

Poster Presenter: Koray Yalcin, TR

pTag Adapter CAR™ T Cells in Preclinical Models 13:15 - 13:15

Poster Presenter: Ulrika Bader, DE

BrainTRUCK: From NKG2D CAR-T to TRUCK in Pediatric CNS 13:15 - 13:15

Tumors
Poster Presenter: Laura Clares-Villa, ES

Flow Cytometry Detection of CAR-T Cells 13:15 - 13:15

Poster Presenter: Silvia Zaninelli, IT

CAR T-cells and Cytopenia 13:15 - 13:15

Poster Presenter: Ahmadreza Arbab, FR

Screening of Novel CARs 13:15 - 13:15

Poster Presenter: Farhana Jahan, FI

On the Path towards Clinical Manufacturing of CAR ??-T Cells 13:15 - 13:15
Poster Presenter: Lorraine Pinot, DE

ASCT before Lymphocyte-apheresis Results in a More 13:15 - 13:15

“Exhausted” T-cells Repertoire
Poster Presenter: Mirko Farina, IT

Donor-derived Myeloid Antigen-directed CAR-T Cells in R/R 13:15 - 13:15

AML in Children
Poster Presenter: Olga Molostova, RU

Thrombopoietin Receptor Agonist after Anti-CD19 CAR-T Cells: 13:15 - 13:15

A Case Report
Poster Presenter: Stefania Bramanti, IT

Changes in Phenotype of T Cells / CD19 CAR-T Cells in the 13:15 - 13:15

Course of Patient Treatment
Poster Presenter: Jonas Wißkirchen, DE

Optimizing LD within T2EVOLVE 13:15 - 13:15

HCT after CAR-T in ALL 13:15 - 13:15

Poster Presenter: Nico Gagelmann, DE

6 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Pembrolizumab after CAR-T 13:15 - 13:15

Poster Presenter: Ana Africa Martin Lopez, ES

Real Life CAR-T for ALL Adult Patients 13:15 - 13:15

Poster Presenter: Eugenio Galli, IT

Autologous Stem Cell Boost in Cytopenia after CAR-T Cells 13:15 - 13:15
Poster Presenter: Michele Wieczorek, IT

Radiation Therapy as Bridge to CAR-T 13:15 - 13:15

Poster Presenter: Marcello Riva, IT

Impacts of CAR-T Cell Therapies in a French Academic Hospital 13:15 - 13:15

Poster Presenter: Lucas Fleta, FR

Successful CAR-T Cell Treatment of JAK1/2 Inhibitor Treatment 13:15 - 13:15

Induced DLBCL

Development of a Method to Measure ADAs against CAR T Cells 13:15 - 13:15

Academic Development of a Lentiviral Vector vs CD19 13:15 - 13:15

Poster Presenter: Alberto Olaya-Vargas, MX

Laboratory BCP-ALL Patient Follow-up after CAR-T Cell 13:15 - 13:15

Treatment
Poster Presenter: Martijn Verbeek, NL

Improving the CAR T-cell Treatment Journey and Access across 13:15 - 13:15
Europe
Poster Presenter: Elise Pennings, NL

Approaching Regulatory Challenges for Engineered T Cell 13:15 - 13:15

Therapies in Europe
Poster Presenter: Paul Franz, DE

ZUMA-25: Brexu-cel in Patients with R/R Rare B-cell 13:15 - 13:15

Malignancies
Poster Presenter: M. Lia Palomba, US

2 Years of Experience and Implications of Nursing Improvement 13:15 - 13:15

Educational Requirements in the United Kingdom’s CAR-T 13:15 - 13:15

Ecosystem
Poster Presenter: Maria Garcia Gomez, GB

Trust and Acceptance AI Applications in Medicine 13:15 - 13:15

Poster Presenter: Anam Ahmed, NL

A Case of Multiply Relapsed B-ALL 13:15 - 13:15

Poster Presenter: Erma Gardner, CA

Starting Material and Sucessfull Manufacturing of Commercial 13:15 - 13:15

Carts
Poster Presenter: Jesus Fernandez-Sojo, ES

CAR-T Cell Dynamics in Treated Patients: A Real-life Cohort 13:15 - 13:15

7 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Study
Poster Presenter: Maddalena Noviello, IT

Early Lymphopheresis Collection Improves CART Fitness in r/r 13:15 - 13:15

DLBCL Patients
Poster Presenter: Tatyana Dubnikov Sharon, IL

Frailty in CART Patients: The Princess Margaret Prospective 13:15 - 13:15

Pilot Study

Siltuximab and Anakinra for CRS and ICANS 13:15 - 13:15

Impact of LDH at Apheresis and Lymphodepletion on Outcome 13:15 - 13:15

after CD19 CAR T Cell Therapy
Poster Presenter: Isabelle Ries, DE

PPI Exploring CAR T-cell Therapy Patients’ Experiences and 13:15 - 13:15
Priorities

Sinus Bradycardia: A Symptom of ICANS after CAR T-cell 13:15 - 13:15

Therapy
Poster Presenter: Sofie-Katrin Kadel, DE

The Role of the CAR-T Advanced Nurse Practitioner in CAR-T 13:15 - 13:15
Cell Therapy Promoting and Adhering to the Immunization
Schedule
Poster Presenter: Mercedes Montoro-Lorite, ES

Different Toxicity in CART Cells: Real-world Experience 13:15 - 13:15

Poster Presenter: Elenii Gavriilaki, GR

CAR-T for Central Nervous System Lymphoma 13:15 - 13:15

Poster Presenter: Marcello Riva, IT

Presentation of a Complex Case Managed by the Synergy of 13:15 - 13:15

Several Professionals
Poster Presenter: Alfonso Parisi, IT

CAR-T Therapy of Diffuse Large B Cell Lymphoma 13:15 - 13:15

Poster Presenter: Milica Miljkovic, SI

Keynote
14:00 - 18:00 On-Demand
KN04 - Keynote Lecture | Novel CAR-T cellular therapy for hematological malignancies
Chair: He Huang, CN

Physicians Session
15:00 - 16:30 Plenary
PS02 - Clinical Indications II - Acute & Chronic Leukaemias
Chair: Annalisa Ruggeri, IT
Chair: John Gribben, GB
Chair: Stephan Mielke, SE
PS02-1 Acute Lymphoblastic Leukemia (ALL) 15:00 - 15:20

8 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Speaker: André Baruchel, FR

PS02-2 Novel targets and technologies for CAR-T cells in AML 15:20 - 15:45
Speaker: Michael Hudecek, DE

PS02-3 Chronic Lymphocytic Leukemia (CLL) 15:45 - 16:10

Speaker: John Gribben, GB

PS02-4 T-cell Acute Lymphoblastic leukemia (T-ALL)/Treating T-Cell 16:10 - 16:30

Non-Hodgkin Lymphoma (T-NHL)
Speaker: Maksim Mamonkin, US

Break
16:30 - 17:00 Foyer
CB1 - Coffee Break in the Foyer

Industry Theatre
16:35 - 16:55 IT
IT1 - Industry Theatre

Best Abstracts
17:00 - 17:30 Plenary
BA1 - Best Abstract Session & Awards
Chair: Anna Sureda, ES
Chair: Michael Hudecek, DE
BA01-1 CAR T Cells Targeting Tumor and Stroma in PDAC 17:00 - 17:10
Oral Presenter: Marc Wehrli, US

BA01-2 Single-cell Dissection of Anti-BCMA CARs in MM 17:10 - 17:20

Speaker: Vladan Vucinic, DE

BA01-3 IF-BETTER-gated CAR T Cells to Safely Target AML with 17:20 - 17:30
Minimal Escape
Oral Presenter: Sascha Haubner, US

Keynote
17:30 - 18:00 Plenary
KN1 - Keynote Lecture
Chair: Chiara Bonini, IT
Chair: Dirk Busch, DE
KN01 Keynote Lecture 1 17:30 - 18:00
Speaker: Marcela Maus, US

Satellite Symposium
18:15 - 19:00 Plenary
SS1 - Satellite Symposium | Optimizing CAR T cell therapy experience in the real world: an outside-
the-box discussion | by Bristol Myers Squibb
Chair: Salomon Manier, FR
SS01-1 Panel discussion > Join our esteemed international panel of 18:15 - 19:00
experts in a conversation that ventures outside the box,

9 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

discussing the latest in multiple myeloma CAR T-cell real-world

evidence. In this live interactive discussion integrating myeloma
and lymphoma expertise, we will explore how real-world
evidence can inform optimal patient identification, efficacy,
toxicity management, and future perspectives of patient care.
Speaker: Marion Subklewe, DE
Speaker: Doris Hansen, US

Meet-the-Experts
19:00 - 20:30 Foyer
MTE02 - Meet-the-experts Session 2
Expert: Carl June, US
Meet Prof June 19:00 - 19:30

Physicians Session
19:00 - 20:00 Foyer
NW1 - Welcome Reception and Poster Exhibition

Meet-the-Experts
19:00 - 20:30 Foyer
MTE01 - Meet-the-Experts Session 1
Expert: Marco Ruella, US
Meet Prof Ruella 19:00 - 19:30

Meet-the-Experts
19:00 - 20:30 Foyer
Welcome Reception | Poster exhibition | Meet the Experts

Meet-the-Experts
19:00 - 20:30 Foyer
MTE03 - Meet-the-Experts Session 3
Expert: Claire Roddie, GB
Meet Prof Roddie 19:00 - 19:30

10 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Friday, 10. February 2023

Keynote
09:00 - 09:50 Plenary
KN2 - Keynote Lecture
Chair: Michelle Kenyon, GB
Chair: Michael Hudecek, DE
Chair: Anna Sureda, ES
KN02 Keynote Lecture 2 09:00 - 09:45

Keynote
09:00 - 18:00 On-Demand
KN04 - Keynote Lecture | Novel CAR-T cellular therapy for hematological malignancies
Chair: He Huang, CN

Poster Session
09:00 - 18:00 Poster Area
Poster

Physicians Session
10:00 - 11:00 Plenary
PS03 - Clinical Indications III - Multiple Myeloma
Chair: Ibrahim Yakoub-Agha, FR
Chair: Paula Rodriguez Otero, ES
PS03-1 Overview 10:00 - 10:20
Speaker: Hermann Einsele, DE

PS03-2 CAR T myeloma ; biomarkers, PK, risk factors 10:20 - 10:40

Speaker: Philippe Moreau, FR

PS03-3 ARIcel in MM/Amyloidosis 10:40 - 11:00

Speaker: Carlos Fernandez de Larrea, ES

Nurses Session
10:00 - 11:00 BR1
NG01 - Opening and Session 1
Chair: Erik Aerts, CH
Chair: Michelle Kenyon, GB
NG0 Opening 10:00 - 10:05

NG01-1 IEC Forum 10:05 - 10:10

Speaker: Ruth Clout, GB

NG01-2 Haematology Nurses and Healthcare Professionals (HNHCP) – 10:10 - 10:20

CAR T-cell therapy learning program: a resource for healthcare
professionals
Speaker: Rose Ellard, GB
Speaker: Erik Aerts, CH

NG01-3 CAR T Cell therapy: past , present, future 10:20 - 10:40

11 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Speaker: Elaine Vickers, GB

NG01-4 The nurse and the patient pathway 10:40 - 11:00

Speaker: Rose Ellard, GB

Break
11:00 - 11:30 Foyer
CB2 - Coffee Break

Industry Theatre
11:05 - 11:25 IT
IT2 - Industry Theatre

Physicians Session
11:30 - 13:00 Plenary
PS04 - Clinical Indications IV - Solid Tumors & Keynote lecture
Chair: Fabio Ciceri, IT
Chair: Annette Künkele, DE
KN03-PS04-1 Keynote lecture on PSMA/Other solid tumors 11:30 - 12:00
Speaker: Carl June, US

PS04-2 Solid tumor pipeline 12:00 - 12:20

Speaker: Sonia Guedan, ES

PS04-3 Advancing CAR T Cell Therapy for Glioblastoma 12:20 - 12:40

Speaker: Christine Brown, US

PS04-4 Paediatrics CAR-Ts 12:40 - 13:00

Speaker: Concetta Quintarelli, IT

Nurses Session
11:30 - 12:15 BR1
NG02 - Session 2
Chair: Ruth Clout, GB
NG02-1 Disease update lymphoma, leukaemia and Myeloma 11:30 - 11:55
Speaker: Ibrahim Yakoub-Agha, FR

NG02-2 Horizon scanning: paediatrics 11:55 - 12:15

Speaker: Marjola Gjergji, IT

Nurses Session
12:15 - 13:00 BR1
NG03 - Session 3
Chair: Ruth Clout, GB
NG03-1 Prehab/ rehab nutrition 12:15 - 12:30
Speaker: Amanda Casirati, IT

NG03-2 Adapted Physical Activity 12:30 - 12:45

Speaker: Nicolas Brelot, FR

12 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

NG03-3 Prehab/ rehab psychology 12:45 - 13:00

Speaker: Vera Hinderling-Baertschi, CH

Break
13:00 - 14:30 Foyer
LB1 - Lunch Break

Industry Theatre
13:05 - 13:25 IT
IT3 - Industry Theatre | Kite: Leader in cell therapy
IT3-1 Leader in cell therapy 13:05 - 13:25
Speaker: Dick Sundh, DE

Satellite Symposium
13:30 - 14:15 Plenary
SS2 - Bringing CAR T into second line in DLBCL | Satellite symposium sponsored by Kite
Chair: Tom van Meerten, NL
SS2-1 Introduction to the symposium 13:30 - 13:33

SS2-2 Defining the unmet need in second-line DLBCL 13:33 - 13:48

Speaker: Wendy Osborne, GB

SS2-2 How has CAR T changed the second-line DLBCL treatment 13:48 - 14:08
landscape?
Speaker: Tom van Meerten, NL

SS2-3 Q&A 14:08 - 14:13

SS2-4 Close 14:13 - 14:15

Physicians Session
14:30 - 15:00 Plenary
PS05 - Patient & Physician perspective on CAR-T Round table
Chair: Natacha Bolaños, ES
Chair: Solène Clavreul, FR
PS05-1 Roundtable discussion 14:30 - 15:00
Speaker: Martine Elias, CA
Speaker: Lorna Warwick, CA

Nurses Session
14:30 - 15:15 BR1
NG04 - Session 4
Chair: Ruth Clout, GB
NG04-1 Early and late infections in patients undergoing CAR T-cell 14:30 - 14:45
Therapy
Speaker: Andriyana Bankova, CH

NG04-2 Experiences of CAR T Cell Therapy: What Nurses report 14:45 - 15:00
Speaker: Martina Spalt, AT

13 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

NG04-3 Advance care planning 15:00 - 15:15

Speaker: Jennifer Vidrine, GB

Keynote
15:00 - 15:30 Plenary
KN5 - Keynote Lecture 5
Chair: Alejandro Madrigal, GB
Chair: Alina Daniela Tanase, RO
KN05 Keynote Lecture: Bringing CAR T to the next generation for 15:00 - 15:30
efficacy and safety
Speaker: Maria Themeli, NL

Nurses Session
15:15 - 16:30 BR1
NG05 - Session 5
Chair: Ruth Clout, GB
NG05-1 Ethical considerations 15:15 - 15:35
Speaker: Anna Castleton, GB

NG05-2 CAR T-Cell Therapies: A Patient's Perspective 15:35 - 15:55

Speaker: Jonathan Clark, NL

NG05-3 CAR T-cell Therapy: Patients- and Family Caregivers' Needs 15:55 - 16:05
Post-treatment
Oral Presenter: Britt Snoek, NL

Nutritional Status during CAR-T Therapy 16:05 - 16:15

Oral Presenter: Nicola Scott, GB

NG05-5 Panel Discussion 16:15 - 16:30

Physicians Session
15:30 - 16:30 Plenary
PS06 - CAR-T Innovation Pipeline
Chair: Maria Themeli, NL
Chair: Ciprian Tomuleasa, RO
PS06-1 Pre-selection of naive T cells and tumor deglycosylation to 15:30 - 15:50
improve CAR-T cell therapy
Speaker: Monica Casucci, IT

PS06-2 Pooled CRISPR Knockin Screens: Reprogramming Therapeutic 15:50 - 16:10

T Cells
Speaker: Franziska Blaeschke, US

PS06-3 Artificial Intelligence for CAR-T 16:10 - 16:30

Speaker: Qasim Rafiq, GB

Break
16:30 - 17:00 Foyer
CB3 - Coffee Break

14 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Industry Theatre
16:35 - 16:55 IT
IT4 - Industry Theatre

Best Abstracts
17:00 - 18:10 Plenary
BA2 - Best Abstract Session
Chair: Ulrich Jaeger, AT
Chair: Sonia Guedan, ES
BA02-1 Association of MTV and Clinical Outcomes in R/R LBCL 17:00 - 17:10
(ZUMA-7)
Oral Presenter: Marie José Kersten, NL

BA02-2 CD19-directed 1xx CAR T Cells in Patients with Rel/Ref DLBCL 17:10 - 17:20
Oral Presenter: M. Lia Palomba, US

BA02-3 ZUMA-5 3-year Follow-up: Axi-cel in Patients with R/R iNHL 17:20 - 17:30
Oral Presenter: Ibrahim Yakoub-Agha, FR

BA02-4 ELARA Clinical Update + Biomarkers and PK 17:30 - 17:40

Oral Presenter: Catherine Thieblemont, FR

BA02-5 EpCAM-directed CAR T-cells against Brain Metastases from 17:40 - 17:50
Lung Cancer
Oral Presenter: Tao Xu, DE

BA02-6 Psychosocial Experiences in Patients Receiving CAR-T 17:50 - 18:00

Compared to Other Therapies
Oral Presenter: Lorna Warwick, CA

BA02-7 Ide-cel versus Standard Regimens in Triple-class-Exposed 18:00 - 18:10

RRMM: Phase 3 KarMMa-3
Oral Presenter: Paula Rodriguez Otero, ES

Nurses Session
17:00 - 17:45 BR1
NG06 - Session 6 and closing
Chair: Erik Aerts, CH
Chair: Michelle Kenyon, GB
NG06-1 Delivering a single national adult CAR T service 17:00 - 17:15
Speaker: Liz Higgins, IE

NG06-2 Capacity building and future proofing 17:15 - 17:30

Speaker: Peter Dreger, DE

NG06-3 Closing remarks 17:30 - 17:45

Speaker: Michelle Kenyon, GB
Speaker: Erik Aerts, CH

15 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Saturday, 11. February 2023

Physicians Session
08:30 - 09:40 Plenary
PS07 - New Academic Initiatives & CAR-T Therapy Networks
Chair: Chiara Bonini, IT
Chair: Natacha Bolaños, ES
PS07-1 GoCART Initiative 08:30 - 08:44
Speaker: Jürgen Kuball, NL

PS07-2 The EBMT Registry: monitoring CAR-T Cells and IECs activities 08:44 - 08:58
in Europe
Speaker: Christian Chabannon, FR

PS07-3 IMI EU T2EVOLVE 08:58 - 09:12

Speaker: Carmen Sanges, DE

PS07-4 Advanced Therapies Network Spain 09:12 - 09:26

Speaker: Jose M. Moraleda, ES

PS07-5 CAR-T Switzerland 09:26 - 09:40

Speaker: Caroline Arber, CH

Physicians Session
08:30 - 09:40 BR1
PS08 - Clinical Management of CAR-T Patients
Chair: Arnon Nagler, IL
Chair: Valentin Ortiz-Maldonado, ES
PS08-1 Patient perspective: CAR-T Journey 08:30 - 08:40
Speaker: Kenneth Casler, FR

PS08-2 Case presentation: adult lymphoma 08:40 - 08:52

Panellist: Peter Dreger, DE

PS08-2 Car-HLH: A devastating complication following Chimeric 08:52 - 09:00

Antigen Receptor T-cell (CAR-T cell) therapy
Oral Presenter: Muhammad Gohar MAQBOOL, GB

PS08-3 Case presentation: adult ALL 09:00 - 09:12

Panellist: Mohamad Mohty, FR
Panellist: Claire Roddie, GB

PS08-3 Successful Treatment of Romiplostim for Persistent 09:12 - 09:20

Thrombocytopenia Following CAR-T Cell Therapy in Phi+ B-
ALL: A Case Report
Oral Presenter: Julien Dereme, CH

PS08-4 Case presentation: Multiple Myeloma 09:20 - 09:40

Panellist: Paula Rodriguez Otero, ES
Panellist: Michel Delforge, BE

16 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

Poster Session
08:30 - 14:30 Poster Area
Poster

Keynote
09:00 - 14:00 On-Demand
KN04 - Keynote Lecture | Novel CAR-T cellular therapy for hematological malignancies
Chair: He Huang, CN

Satellite Symposium
09:45 - 10:30 Plenary
SS4 - CAR-T Cell Therapy expends the horizon for patients with Multiple Myeloma | Satellite
Symposium by Janssen
Chair: Mohamad Mohty, FR
SS4-1 Welcome and introduction 09:45 - 09:50
Speaker: Mohamad Mohty, FR

SS4-2 Where are we now with CAR-T cell therapy in MM? 09:50 - 10:05
Speaker: Paula Rodriguez Otero, ES

SS4-3 Where are we going with CAR-T cell therapy in MM? 10:05 - 10:20
Speaker: Pieter Sonneveld, NL

Panel discussion with Q&A | Closing remarks 10:20 - 10:30

Physicians Session
10:40 - 11:50 Plenary
PS09 - Advanced concepts for CAR-T manufacturing
Chair: Halvard Bönig, DE
Chair: Concetta Quintarelli, IT
PS09-1 Overview 10:40 - 10:55
Speaker: Ulrike Köhl, DE

PS09-2 Point-of-care CAR-T manufacture 10:55 - 11:10

Speaker: Alvaro Urbano Ispizua, ES

PS09-3 Rapid CAR-T manufacture 11:10 - 11:25

Speaker: Nina Worel, AT

PS09-4 Point-of-care ATMP manufacture 11:25 - 11:40

Speaker: Harry Dolstra, NL

PS09-5 Panel discussion 11:40 - 11:50

Physicians Session
10:40 - 11:50 BR1
PS10 - Toxicity Management
Chair: Zinaida Peric, HR
Chair: Patrick Hayden, IE
PS10-1 European Guidelines 10:40 - 10:55
Speaker: Ibrahim Yakoub-Agha, FR

17 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

PS10-2 Hematologic Toxicity 10:55 - 11:10

Speaker: Marion Subklewe, DE

PS10-3 COVID 11:10 - 11:25

Speaker: Marie José Kersten, NL

PS10-4 Panel discussion 11:25 - 11:50

Physicians Session
12:00 - 13:10 Plenary
PS11 - International Session - Access to CAR-T on a Global Scale
Chair: Christian Chabannon, FR
Chair: Ulrike Köhl, DE
PS11-1 South America 12:00 - 12:12
Speaker: Vanderson Rocha, BR

PS11-2 Central and Eastern Europe 12:12 - 12:24

Speaker: Roman Hajek, CZ

PS11-3 South Africa 12:24 - 12:36

Speaker: Candice Hendricks, ZA

PS11-4 Canada 12:36 - 12:48

Speaker: Kevin Hay, CA

PS11-5 India 12:48 - 13:00

Speaker: Gaurav Narula, IN

PS11-6 Roundtable discussion 13:00 - 13:10

Speaker: Martine Elias, CA

Physicians Session
12:00 - 13:10 BR1
PS12 - Failure of CAR-T - What is next?
Chair: Raffaella Greco, IT
Chair: Natacha Bolaños, ES
Chair: Koray Yalcin, TR
PS12-1 Patient perspective: Fear of relapse 12:00 - 12:10
Speaker: Lorna Warwick, CA

PS12-2 Case presentation: adult lymphoma 12:10 - 12:22

Panellist: Paolo Corradini, IT

PS12-2 Acute myeloid Leukemia after Anti-CD19 CAR-T Therapy in a 12:22 - 12:30
Patient with Relapsed High-grade non-Hodgkin B Lymphoma
Oral Presenter: Juan Francisco López Rodríguez, ES

PS12-3 Case presentation: Paediatric ALL 12:30 - 12:42

Panellist: Sara Ghorashian, GB
Panellist: Annette Künkele, DE

PS12-3 Inotuzumab Ozogamicin as a Bridge to Allogeneic 12:42 - 12:50

Hematopoietic Stem Cell Transplantation in Relapsed Pediatric

18 / 19
Scientific programEBMT-EHA 5th European CAR T-Cell Meeting 9 -11 February 2023 EBMT-EHA 5th European CAR T-cell Meeting

B-cell Precursor Acute lymphoblastic Leukemia after

CD19-targeted CAR T-cell Therapy
Oral Presenter: Margo Aertgeerts, BE

PS12-4 Case presentation: Multiple Myeloma 12:50 - 13:10

Panellist: Maria Victoria Mateos, ES
Panellist: Sophia Danhof, DE

Break
13:10 - 13:30 Foyer
CB4 - Lunch boxes delivery

Best Abstracts
13:30 - 14:00 Plenary
BA3 - Best Abstract Session
BA03-1 Third-generation CAR T-cells incorporating a TLR2 co- 13:30 - 13:40
stimulatory domain combine enhanced cytotoxicity with
reduced inflammatory cytokine production: Pre-clinical and
phase 1 clinical trial findings
Oral Presenter: Yasmin Nouri, NZ

BA03-2 Impact of the gastrointestinal microbiota in the efficacy of CART- 13:40 - 13:50
cell therapy in patients with multiple myeloma
Oral Presenter: Mireia Uribe-Herranz, ES

BA03-3 Dual Targeting of Hodgkin’s Lymphoma by Anti-CD30 CAR-T 13:50 - 14:00

Cells Co-transduced with an Anti-PDL1 Costimulatory Receptor
to Overcome the Immunosuppressive Microenvironment
Oral Presenter: Vincenzo Maria Perriello, IT

Keynote
14:00 - 14:30 Plenary
KN6 - Keynote Lecture 6
Chair: Anna Sureda, ES
Chair: Michael Hudecek, DE
KN06 Keynote Lecture 6 14:00 - 14:30
Speaker: Michel Sadelain, US

19 / 19